Vital KSK Holdings (3151) Fundamentals 2026 — P/E 11.0x, Revenue Analysis | SniperIQ
Vital KSK Holdings (3151) is a JP-listed Healthcare company in Medical - Distribution with a market capitalization of ¥80.7B, trading at ¥1668.00 on the JPX. This SniperIQ fundamentals page covers Vital KSK Holdings's valuation (P/E 11.0x, P/B 0.7x), profitability (net margin 1.2%), revenue (¥610.5B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Vital KSK Holdings's market cap?
Vital KSK Holdings (3151) has a market capitalization of approximately ¥80.7B, trading at ¥1668.00 on the JPX. Market cap moves with the live share price.
What is Vital KSK Holdings's P/E ratio?
Vital KSK Holdings's trailing twelve-month P/E ratio is 11.0x, with a price-to-book (P/B) of 0.7x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Vital KSK Holdings?
Vital KSK Holdings runs a net profit margin of 1.2%, a gross margin of 8.1%, and an operating margin of 0.7%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Vital KSK Holdings generate?
Vital KSK Holdings reported revenue of ¥610.5B for fiscal year 2025, with net income of ¥7.4B and earnings per share (EPS) of 152.28. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Vital KSK Holdings pay a dividend?
Vital KSK Holdings offers a trailing dividend yield of about 4.2%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Vital KSK Holdings financially healthy?
Vital KSK Holdings carries a debt-to-equity ratio of 0.06x and a current ratio of 1.06x, with a market beta of 0.25. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Vital KSK Holdings a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Vital KSK Holdings (3151) the key facts are: market cap ¥80.7B, P/E 11.0x, revenue ¥610.5B, 52-week range 1220-1678. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Vital KSK Holdings's full fundamentals live
Get Vital KSK Holdings's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.